Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SCYX
stocks logo

SCYX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
8.10M
+729.07%
0.127
-240.74%
141.00K
-45.14%
-0.155
+40.91%
147.00K
-89.22%
-0.150
+7.14%
Estimates Revision
The market is revising Downward the revenue expectations for SCYNEXIS, Inc. (SCYX) for FY2025, with the revenue forecasts being adjusted by -18.5% over the past three months. During the same period, the stock price has changed by -24.83%.
Revenue Estimates for FY2025
Revise Downward
down Image
-18.5%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+12.32%
In Past 3 Month
Stock Price
Go Down
down Image
-24.83%
In Past 3 Month
Wall Street analysts forecast SCYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCYX is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast SCYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCYX is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.669
sliders
Low
3.00
Averages
3.50
High
4.00
Current: 0.669
sliders
Low
3.00
Averages
3.50
High
4.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for SCYNEXIS Inc (SCYX.O) is -2.14, compared to its 5-year average forward P/E of -0.56. For a more detailed relative valuation and DCF analysis to assess SCYNEXIS Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.56
Current PE
-2.14
Overvalued PE
21.30
Undervalued PE
-22.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.36
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.50
Undervalued EV/EBITDA
-1.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.33
Current PS
0.00
Overvalued PS
16.14
Undervalued PS
-1.49
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SCYX News & Events

Events Timeline

(ET)
2025-11-19
07:06:32
Scynexis Finalizes Transfer of BREXAFEMME NDA to GSK
select
2025-11-17 (ET)
2025-11-17
10:19:34
Scynexis reveals funding for partnership between Hackensack Meridian and Johns Hopkins
select
2025-11-05 (ET)
2025-11-05
17:59:35
Scynexis Announces Q3 Earnings Per Share of 17 Cents, Below Consensus Estimate of 20 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-17Newsfilter
Scynexis Reveals Federal Support for Partnership Between Hackensack Meridian CDI and Johns Hopkins Researchers to Create Innovative Therapies, Including New Fungerps, for Resistant Fungal Infections

  • Federal Grant Announcement: SCYNEXIS, Inc. has received a five-year federal grant of $7 million annually to support the development of new antifungal therapeutics, particularly next-generation triterpenoid antifungals (fungerps), aimed at combating resistant fungal infections.

  • Research Collaboration: The grant will establish a Center of Excellence in Translational Research (CETR) in collaboration with Hackensack Meridian Center for Discovery and Innovation and Johns Hopkins Bloomberg School of Public Health, focusing on advancing fungerp candidates from preclinical stages to IND-ready status.

  • Fungal Infection Statistics: Approximately four million deaths annually are attributed to fungal infections globally, highlighting the urgent need for new therapeutics to address the growing threat of resistant fungal pathogens.

  • Triterpenoid Antifungals Overview: Triterpenoid antifungals represent a novel class of glucan synthase inhibitors, with the first compound, Ibrexafungerp, already approved for treating vulvovaginal candidiasis, while additional candidates are in various stages of development to tackle multidrug-resistant fungal infections.

[object Object]
Preview
9.5
11-06Newsfilter
SCYNEXIS Announces Financial Results for Q3 2025 and Shares Corporate Update

  • Financial Agreement with GSK: SCYNEXIS will receive $24.8 million from GSK as part of resolving a disagreement over the Phase 3 MARIO study, which SCYNEXIS has agreed to terminate. This payment will enhance the company's cash runway to over two years.

  • SCY-247 Development Progress: Following positive Phase 1 results for SCY-247, SCYNEXIS plans to initiate a Phase 1 study for its IV formulation and a Phase 2 study for invasive candidiasis, with proof of concept data expected in 2026.

  • Commitment to BREXAFEMME®: GSK is focused on relaunching BREXAFEMME®, with plans to transfer the NDA by year-end, potentially leading to SCYNEXIS receiving up to $146 million in annual sales milestones and royalties.

  • Q3 2025 Financial Results: SCYNEXIS reported a net loss of $8.6 million for Q3 2025, with total revenue primarily from license agreements. The company is managing its expenses effectively, resulting in a cash balance of $37.9 million as of September 30, 2025.

[object Object]
Preview
6.0
10-28Benzinga
Guggenheim Reiterates Buy Rating on SCYNEXIS, Adjusts Price Target to $3

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform is designed to help traders win in the markets every day with accurate stock market intelligence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is SCYNEXIS Inc (SCYX) stock price today?

The current price of SCYX is 0.669 USD — it has increased 1.36 % in the last trading day.

arrow icon

What is SCYNEXIS Inc (SCYX)'s business?

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

arrow icon

What is the price predicton of SCYX Stock?

Wall Street analysts forecast SCYX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCYX is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is SCYNEXIS Inc (SCYX)'s revenue for the last quarter?

SCYNEXIS Inc revenue for the last quarter amounts to 334.00K USD, decreased -49.39 % YoY.

arrow icon

What is SCYNEXIS Inc (SCYX)'s earnings per share (EPS) for the last quarter?

SCYNEXIS Inc. EPS for the last quarter amounts to -0.17 USD, increased 183.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for SCYNEXIS Inc (SCYX)'s fundamentals?

The market is revising Downward the revenue expectations for SCYNEXIS, Inc. (SCYX) for FY2025, with the revenue forecasts being adjusted by -18.5% over the past three months. During the same period, the stock price has changed by -24.83%.
arrow icon

How many employees does SCYNEXIS Inc (SCYX). have?

SCYNEXIS Inc (SCYX) has 28 emplpoyees as of December 05 2025.

arrow icon

What is SCYNEXIS Inc (SCYX) market cap?

Today SCYX has the market capitalization of 28.07M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free